Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
about
An observational study of bimatoprost 0.01% in patients on prior intraocular pressure-lowering therapy: the Canadian Lumigan(®) RC Early Analysis Review (CLEAR) trialClinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertensionA randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprostThe impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies.Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials.An observational study of bimatoprost 0.01% in treatment-naïve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial.Fixed-combination and emerging glaucoma therapies.Diurnal intraocular pressure with bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in healthy subjects.Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patientsBimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors.Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%).In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%.Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides.Corneal neovascularization and ocular irritancy responses in dogs following topical ocular administration of an EP4-prostaglandin E2 agonist.Recurrent serous macular detachment after topical ocular hypotensive medication.A multicentre evaluation of the effect of patient education on acceptance of hyperaemia associated with bimatoprost therapy for glaucoma or ocular hypertension.Topical application of 0.005% latanoprost increases episcleral venous pressure in normal dogs.Effect of topical ophthalmic latanoprost 0.005% solution alone and in combination with diclofenac 0.1% solution in healthy horses: a pilot study.
P2860
Q33706842-2056EF50-8242-4C17-A95A-143965EBF1EAQ34043309-E86CA911-EED4-4954-A038-18045FA6C4A5Q34399842-F96E49C1-C544-4F84-BC79-9DE152D8B375Q34731426-B96DBEAE-FCF7-4940-8EA9-6E09587AC6D5Q35050234-60388633-4039-4FDD-90D5-49B637F1076EQ36487013-1824CC3A-5216-4815-9612-1A7A8A7A73C8Q36866626-F340618E-94E4-4A97-889C-A5BB27DFA2C5Q37555451-77813A09-A1E0-4ABD-8177-E16BCE3120DCQ37697869-16509E69-C8EF-4629-A8C0-C29181C0670BQ39875047-888FA11F-2422-48AF-A97A-CD92441E8BBCQ41352665-FAED022C-E7D8-4C0D-98C3-CC5B96DA356EQ42581183-4BBF3592-D57E-41E4-B811-84D32EE0364AQ42943389-82F9FFD1-F6E8-4999-B270-F3DE055D230BQ43222813-89AD58B8-FC91-477F-9DD4-A37F3249C1EBQ46552921-11F06F09-AC15-4415-A352-6C4723AD1D73Q46693556-0E4E7BCB-6145-464F-B5EC-261C434971CAQ51381582-2DE64FAB-016C-4675-B6DD-022869F0047CQ53559582-FC240A90-532A-4407-8BCC-C8AF5D6D249B
P2860
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
@ast
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
@en
type
label
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
@ast
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
@en
prefLabel
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
@ast
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
@en
P2093
P2860
P1476
Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapy.
@en
P2093
David F Woodward
Larry A Wheeler
Michael Holland
Tsung-Hua Lin
Yang-Dar Yuan
P2860
P304
P356
10.1111/J.1527-3466.2005.TB00168.X
P577
2005-01-01T00:00:00Z